

## Molecules: Inositol 1,4,5-trisphosphate receptors (InsP<sub>3</sub>R)

Rahul Chandrasekhar David I. Yule and Liwei Wang

Department of Pharmacology and Physiology, University of Rochester. Rochester NY 14642

David\_Yule@urmc.rochester.edu

Version 2.0, October 19, 2017 [DOI: 10.3998/panc.2017.07]

**Gene Symbols:** [ITPR1](#), [ITPR2](#), [ITPR3](#)


**Other Names:** IP<sub>3</sub>R1, IP<sub>3</sub>R2, IP<sub>3</sub>R3

respectively) that share 60-70% sequence homology (47).

### 1. General: The role of InsP<sub>3</sub>R in pancreatic acinar and other cells

The classical pathway linking stimulation by neurotransmitters and hormones to changes in phosphoinositide metabolism and the subsequent InsP<sub>3</sub> induced Ca<sup>2+</sup> release was in large part documented by work carried out in exocrine cells, in particular, acinar cells isolated from the exocrine pancreas (62). In seminal work using permeabilized rat pancreatic acini, Streb and colleagues demonstrated that the addition of InsP<sub>3</sub> resulted in Ca<sup>2+</sup> release from a non-mitochondrial Ca<sup>2+</sup> store (54). This store was later identified to be the endoplasmic reticulum (ER) through experiments where sub-cellular fractions from pancreatic cells were isolated and exposed to InsP<sub>3</sub> (6, 53). Ca<sup>2+</sup> release is rapid, occurring as quickly as 1s following secretagogue stimulation of acinar cells. Ca<sup>2+</sup> release is also isomer specific, with other structurally related inositol phosphates shown to be far less efficacious in releasing Ca<sup>2+</sup> (54). The target protein for InsP<sub>3</sub> binding was later identified as the inositol 1,4,5-trisphosphate receptor (InsP<sub>3</sub>R) (56). Strikingly, the secretion of digestive enzymes from pancreatic acinar cells has been shown to be entirely dependent on the activation of InsP<sub>3</sub>R and the resulting elevation in intracellular [Ca<sup>2+</sup>] (22). The receptor is encoded by 3 distinct genes in mammalian cells (ITPR1, ITPR2, ITPR3) that generate 3 monomeric isoforms (R1, R2, R3

Originally purified and cloned from rat cerebellum, the full length InsP<sub>3</sub>R forms a tetrameric cation selective channel *in vivo* (40). The three isoforms of InsP<sub>3</sub>R exhibit overlapping patterns of expression, with most cells and tissues expressing more than one isoform (63). Western blotting and quantitative PCR has revealed that there is relatively equal expression of the R2 and R3 isoforms in pancreas, with R1 only constituting ~3% of the total InsP<sub>3</sub>R (63). The importance of R2 and R3 isoforms to pancreatic Ca<sup>2+</sup> signaling is most evident in studies employing InsP<sub>3</sub>R



**Figure 1:** Localization of InsP<sub>3</sub>R<sub>s</sub> in pancreatic acinar cells. Immunofluorescence localizations in pancreatic lobules of InsP<sub>3</sub>R<sub>s</sub> by confocal microscopy demonstrate the localization of InsP<sub>3</sub>R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and amylase (A,B,C,D respectively) respectively. All 3 isoforms are predominantly localized to the apical pole of acinar cells directly abutting the plasma membrane (arrows in panels A-C). R<sub>1</sub> and R<sub>3</sub> also appeared to localize to perinuclear structures. (Scale bar = 10 μm). (69)


knockout (KO) mice (22). Although single R2 or R3 KO mice were found to have no observable ill effects or phenotypic alterations, double R2/R3 KO mice typically gained less body weight post-natally compared to single KO or WT mice. Furthermore, double KO mice tended to lose weight rapidly post weaning and typically died 4 weeks after birth. These observations were attributed to the key role the R2 and R3 isoforms play in the secretion of saliva and exocytosis of digestive enzymes from exocrine glands and the resulting inability of double KO mice to swallow or properly digest dry adult food. Indeed, double KO mice were rescued and reached body weights comparable to WT when a fed pre-digested wet mash diet or an elemental diet. Pancreatic acinar cells from R2/R3 double KO mice were also found to accumulate zymogen granules and failed to secrete zymogen granules on stimulation with secretagogues. The study also highlights the inability of R1 to rescue double R2/R3 KO mice (22).

The fidelity and specificity of the  $\text{Ca}^{2+}$  signal required for exocytosis is thought to be largely determined by the differential expression, localization and modulation exhibited by the 3  $\text{InsP}_3\text{R}$  isoforms (21). For the most part,  $\text{InsP}_3\text{Rs}$  are predominantly localized to the ER, although the golgi, nucleus, plasma membrane, peroxisomes and endolysosomal vesicles have also been reported to express small levels of  $\text{InsP}_3\text{Rs}$ . Pancreatic acinar cells are highly

polarized, both functionally and morphologically and  $\text{InsP}_3\text{Rs}$  are predominantly expressed in ER extensions in the apical regions juxtaposed to the acinar lumen (**Figure 1**) (34, 36, 42, 69). Using fluorescence imaging techniques, studies have shown that stimulating  $\text{InsP}_3$  generation in these cells results in the initiation of  $\text{Ca}^{2+}$  signals in the apical regions, followed by the propagation basally of a  $\text{Ca}^{2+}$  wave that is facilitated by peripheral  $\text{InsP}_3\text{Rs}$ . Stimulation of basal secretagogue receptors as well as uncaging  $\text{InsP}_3$  in various regions of the cell also confirm that  $\text{Ca}^{2+}$  signals initiate in apical regions of the pancreatic acinar cell (5, 20, 31, 58, 65).

## 2. Structural features of the $\text{InsP}_3\text{R}$


Based on the sequence homology, all three isoforms of  $\text{InsP}_3\text{R}$  are predicted to have the same general structural domains (12). Specifically, the  $\text{InsP}_3\text{R}$  monomer is conventionally divided into 3 functional domains: an N-terminal ligand binding domain (LBD), a coupling and modulatory domain and a C-terminal transmembrane domain (TMD) that contains the channel (21) (**Figure 2A**). To date, the majority of structural insights were from the investigations of R1, including the recent structures of R1 revealed by cryo-EM (**Figure 2B and 2C**) and x-ray crystallography (26). Therefore, in this review, the locations of common functional modules in  $\text{InsP}_3\text{R}$ , which are also present in R2 and R3 at homologous regions, are described using the



**Figure 2:** Illustration of R1 depicting location of suppressor domain, ligand binding core, regulation and coupling domain and channel domain (A). Structure of R1 revealed by Cryo-electron microscopy at near atomic resolution of 4.7 Å (B and C). (B) is a side view along membrane plane of a R1 monomer. (C) is a tetrameric R1 viewed from cytosol. Each monomer of the tetramer are color-coded. Figures are adapted from (19)

amino acid sequence of R1. InsP<sub>3</sub> binding is mediated by the 'core' ligand binding domain, which constitutes amino acids (AA) 224-578 of the LBD. This region contains 10 conserved positively charged arginine and lysine residues (3 critical, R265, K508, R511) that are thought to allosterically coordinate the negatively charged PO<sub>4</sub><sup>3-</sup> groups of InsP<sub>3</sub> in a binding pocket (67). By using concatenated subunits (1, 18), our group has recently reported that InsP<sub>3</sub> molecules must be bound to each monomer of the four subunits to open the channel and activate InsP<sub>3</sub>R (2). This gating mechanism ensures the fidelity of InsP<sub>3</sub> induced calcium release and may provide mechanistic insight into diseases where mutations have an impact on InsP<sub>3</sub> binding to the receptor. The three isoforms have differing InsP<sub>3</sub> binding affinities that are regulated by the first 223 AA of the LBD, termed the suppressor domain (SD). Specifically, competitive InsP<sub>3</sub> binding assays using GST fusion constructs encoding AA 1-604 demonstrate that R2 has an 11-fold greater affinity (K<sub>d</sub>) for InsP<sub>3</sub> compared to R3 (14 nM vs. 163 nM), with R1 having an intermediate affinity (49.5 nM) (29). Similar studies in pancreatic acini revealed a K<sub>d</sub> of 6 nM (24), comparable to that of R2, while permeabilized Ca<sup>2+</sup> release assays in acinar cells demonstrated an EC<sub>50</sub> for InsP<sub>3</sub> of 0.8 μM (45) (**Figure 3**). Deletion of the suppressor domain (SD) results in the loss of distinct InsP<sub>3</sub> affinities between the isoforms and a 10-100 fold increase in InsP<sub>3</sub> affinity (29). Despite an

increased InsP<sub>3</sub> binding affinity, deletion of the SD also results in the loss of channel activity, indicating that the SD is required for inducing InsP<sub>3</sub>R activation and Ca<sup>2+</sup> release. The pivotal role of SD for InsP<sub>3</sub>R activation was also strongly supported by Cryo-EM structure of homotetrameric R1 solved at near-atomic resolution (19). The Serysheva group showed that the SD domain forms inter-subunit interactions with ARM2, ARM3, β-TF2 and CTD domains of adjacent subunits, which may underlie a direct functional coupling between the N- and C-terminus of the receptor (19). Based on hydropathy plots, the TMD is similar in structure to that of RyRs and voltage gated K<sup>+</sup>, Na<sup>+</sup> and Ca<sup>2+</sup> channels and constitutes 6 putative transmembrane regions (TM1-6) (16). The TMD is responsible for the ER targeting (44, 46) and for the oligomerization of the InsP<sub>3</sub>R into tetramers, which occurs co-translationally (30). Lastly, TM5 and 6 forms the pore through which Ca<sup>2+</sup> is conducted (48). The loop between TM5 and 6 contains a selectivity filter (GVGD; similar to the super family of cation selective channels) that provides some degree of cation selectivity to the InsP<sub>3</sub>R (21). However, it is poorly Ca<sup>2+</sup> selective and allows conduction of monovalent cations (Ca<sup>2+</sup>:K<sup>+</sup> = 6:1). In fact, it is believed that "functional" Ca<sup>2+</sup> selectivity of InsP<sub>3</sub>R is primarily determined by virtue of SERCA being a highly selective Ca<sup>2+</sup> pump and Ca<sup>2+</sup> being by the far the most abundant cation in the ER. To "gate" and



**Figure 3:** (A) Permeabilized cell Ca<sup>2+</sup> release assay in acinar cells. Isolated pancreatic acini were loaded with fura2/ra prior to permeabilization with β-escin. ER is loaded through SERCA upon application of Ca<sup>2+</sup> containing buffer containing MgCl<sub>2</sub>, and ATP, as indicated by the increase in fluorescence ratio. Removal of MgCl<sub>2</sub> deactivates SERCA and (B) addition of varying [InsP<sub>3</sub>] releases from stores as indicated by the decrease in fluorescence ratio. (C) Concentration response analysis for InsP<sub>3</sub>. EC<sub>50</sub> for InsP<sub>3</sub> is 0.8 μM (10)

open the channel, . The CT tail (last 160 AA) and the large (1700 AA) but less conserved modulatory domain contains putative binding sites for the numerous modulators of  $\text{InsP}_3\text{R}$  activity (68). These modulators, which include  $\text{Ca}^{2+}$ , ATP and PKA, all contribute in distinct ways to the differential  $\text{Ca}^{2+}$  release profiles encoded by the 3 isoforms.

### 3. Modulation of the $\text{InsP}_3\text{R}$

Cytosolic  $\text{Ca}^{2+}$  is the most important regulator of  $\text{InsP}_3\text{Rs}$ , modulating activity in a biphasic manner (14). Numerous putative  $\text{Ca}^{2+}$  binding sites have been identified, and  $\text{Ca}^{2+}$  has been shown to induce dramatic conformational changes in R1 (3, 4, 25, 49, 50). For the most part, studies have shown that in the presence of  $\text{InsP}_3$ , low to optimal  $[\text{Ca}^{2+}]$  (300 nM) stimulates channel activity while higher cytosolic  $[\text{Ca}^{2+}]$  inhibits it (14). To explain this biphasic regulation, Foskett and collaborators have proposed a model in which  $\text{InsP}_3\text{R}$  activity is regulated by two distinct  $\text{Ca}^{2+}$  binding sites: a stimulatory and an inhibitory site. Under resting conditions, the inhibitory site has a higher affinity for  $\text{Ca}^{2+}$  than the stimulatory site. Accordingly, this site is occupied at resting conditions and inhibits  $\text{InsP}_3\text{R}$  activity. The binding of  $\text{InsP}_3$  decreases the inhibitory sites' affinity for  $\text{Ca}^{2+}$ , thereby allowing  $\text{Ca}^{2+}$  to bind to the stimulatory site and positively regulating channel activity. The downstroke of the biphasic curve is the result of  $\text{Ca}^{2+}$  binding to the inhibitory sites due to cytosolic  $[\text{Ca}^{2+}]$  being elevated beyond 300 nM (57). In effect, they suggest that  $\text{Ca}^{2+}$  is only an essentially  $\text{InsP}_3\text{R}$  co-agonist, with  $\text{InsP}_3$ 's sole role being simply to modulate  $\text{Ca}^{2+}$  sensitivities (37).

Cytosolic ATP has also been shown to differentially modulate the activity of all 3 isoforms in an allosteric manner. This mode of regulation is thought to link the metabolic status of the cell to the  $\text{Ca}^{2+}$  release. Specifically, studies show that R2 is only modulated by ATP at sub-maximal  $[\text{InsP}_3]$  while R1 and R3 activity is affected

irrespective of  $[\text{InsP}_3]$ , implying that ATP is required for maximal activity of R1 and R3 (8, 9). Each isoform also differs in its affinity for ATP, with R2 having 3 fold and 10 fold higher affinities than R1 and R3, respectively (8). ATP binding was originally believed to occur at Walker A like motifs (G-X-G-X-X-G) that exist in each isoform. One such motif, called ATPB, is conserved across all 3 isoforms. Additionally, R1 contains 2 other sites: ATPA and ATPC, the latter only being found in the S2- variant which is expressed in peripheral tissues (59). Recently, mutagenesis studies have demonstrated that only the ATPB site in R2 is important in mediating the modulatory effects of ATP (45) and this regulation is important for defining the sensitivity of  $\text{Ca}^{2+}$  release in pancreatic acinar cells (24). In contrast, the ATPB sites in R1 and R3, in addition to the ATPA and ATPC sites in R1, play no role in modulating  $\text{InsP}_3\text{R}$  activity through ATP.

Further, another level of receptor regulation results from the subunit composition of  $\text{InsP}_3\text{R}$ . Most cells express more than one isoform of  $\text{InsP}_3\text{R}$ ; as a result, different isoforms of  $\text{InsP}_3\text{R}$  display overlapping expression patterns (63). Extensive studies with various experimental techniques, including cross-linking (15, 43), immunostaining (27, 33, 34, 69), and co-immunoprecipitation (1, 64), have consistently demonstrated that  $\text{InsP}_3\text{R}$  can be hetero-tetrameric channels formed from at least two isoforms of  $\text{InsP}_3\text{R}$ . An obvious question is what is the contribution of each subunit in a hetero-tetramer? Our lab showed that an individual subtype can either contribute equally, or dictate the  $\text{Ca}^{2+}$  release properties of the hetero-tetrameric  $\text{InsP}_3\text{R}$ , depending on the presence and the concentrations of key regulators (ATP and  $\text{Ca}^{2+}$ ) (17). In the context of the pancreas, R2 and R3 are the predominant isoforms and form hetero-tetramers accounting for the major proportion of the  $\text{InsP}_3\text{R}$  (63). A hetero-tetramer containing two R2 and two R3 is predicted to exhibit blended channel activities under optimal conditions; in contrast, R2 in the same hetero-

tetramer can dictate the channel activities under suboptimal conditions (17).

Region-specific proteolysis is a novel form of regulation for all three isoforms of InsP<sub>3</sub>R. R1 has been well demonstrated to be a substrate for the intracellular cysteine proteases, caspase and calpain (28, 32). However, the functional consequences of receptor fragmentation are a subject of considerable debate. Recent evidence strongly suggests that region-specific proteolysis modifies R1 channel regulation (51, 60, 61). Specifically, stimulation of caspase or calpain fragmented R1 results in Ca<sup>2+</sup> signals with distinct temporal characteristics and can activate alternative signaling pathways (51, 61). Further studies are necessary to gauge if R2 and R3 are subject to similar regulation.

Lastly, protein kinase A (PKA) mediated phosphorylation has been shown to directly increase InsP<sub>3</sub>R Ca<sup>2+</sup> flux and single channel activity of R1 and R2 albeit by phosphorylation at different residues. Specifically, studies show that PKA mediated phosphorylation at S1598 and S1755 on R1 and S937 on R2 significantly enhance Ca<sup>2+</sup> release and single channel activity (7, 11, 68). Conversely, no effects on Ca<sup>2+</sup> release through R3 have been observed after PKA stimulation, despite evidence that R3 is phosphorylated by PKA at 3 sites *in vivo* (52, 68). Thus far, no single channel studies have been performed on R3 to rule out any PKA mediated effects on channel activity.

InsP<sub>3</sub>Rs are also regulated and bound by numerous other kinases and accessory proteins, including cGMP protein kinase (PKG), Akt kinase, FK506 binding protein, calmodulin, CaBP, IRBIT, Bcl-2/XL, cytochrome C, RACK and Erp44 (21).

## 4, Tools available to study the InsP<sub>3</sub>R

### A. Antibodies

A multitude of commercially available isoform specific antibodies can be utilized to probe for each isoform of the InsP<sub>3</sub>R. Additionally, there are antibodies that detect all 3 isoforms

- InsP<sub>3</sub>R1 Rabbit polyclonal (H-80) from Santa Cruz (sc-28614); epitope corresponding to AA 1894-1973 in the cytosolic modulatory domain
- InsP<sub>3</sub>R1, UC Davis/NIH NeuroMab Facility, clone L24/18; epitope against AA 2680-2749 in C-terminus
- InsP<sub>3</sub>R3 Goat polyclonal (C-20) from Santa Cruz (sc-7277); epitope corresponding to C-terminus
- InsP<sub>3</sub>R3 purified mouse monoclonal from BD Transduction Laboratories (Cat: 610313)
- InsP<sub>3</sub>R1/2/3 Rabbit polyclonal (H-300) from Santa Cruz (sc-28613); epitope corresponding to AA 2402-2701 in C-terminus of InsP<sub>3</sub>R-2 (human)

### B. cDNA

Accession number:

InsP<sub>3</sub>R1: rat, 55925609

InsP<sub>3</sub>R2: mouse, 60593031

InsP<sub>3</sub>R3: rat, 6981109

### C. Cell Lines

SHSYFY Neuroblastoma: 99% InsP<sub>3</sub>R1 (63)

AR42J Rat pancreatoma: 86% InsP<sub>3</sub>R2; 12% InsP<sub>3</sub>R1; 2% InsP<sub>3</sub>R3 (63)

RINM5F Mouse insulinoma: 96% InsP<sub>3</sub>R3; 4% InsP<sub>3</sub>R1(63)

DT40 triple knockout cell lines: Kurosaki and colleagues have generated a DT40 chicken B lymphocyte cell line with the endogenous InsP<sub>3</sub>Rs stably knocked out (55). These triple knockout cells can subsequently be stably transfected with constructs encoding individual mammalian InsP<sub>3</sub>R isoforms, allowing the study of activity and regulation of each isoform in isolation. These cell lines are available on request from our laboratory.

HEK triple knockout cell line: David Yule and colleagues have generated HEK triple

knockout cell line with the endogenous InsP<sub>3</sub>Rs stably knockout (2). In addition to DT40 triple knockout cell line, HEK triple knockout cell line provides an alternative mammalian InsP<sub>3</sub>R null background system for research.

#### D. Mouse Lines

InsP<sub>3</sub>R-1 knockout mice (39)  
InsP<sub>3</sub>R-2 (35) and R-3 single and double knockout mice (22)

#### E. Agonists/Antagonists/

##### Agonists

Commercially available InsP<sub>3</sub>: D-myo-inositol 1,4,5-trisphosphate hexapotassium salt; Enzo Life Sciences (cat: ALX-307-00)  
Cells are often stimulated with Gq coupled GPCR agonists to stimulate InsP<sub>3</sub> production.

Agonists include acetylcholine, trypsin and cholecystokinin.

##### Antagonists

Heparin (66); Caffeine (13); 2-Aminoethoxydiphenyl borate (2-APB) (38, 41); Xestospongine (23)

#### F. Techniques used to study InsP<sub>3</sub>R function

See review by Betzenhauser MJ., Wagner LE., Won JW and Yule DI. (2008) Studying isoform-specific inositol 1,4,5-trisphosphate receptor function and regulation. *Methods* 46, pp: 177-182. (10)  
Betzenhauser, Matthew J., Won, Jong Hak, Park, Hyungseo and Yule, David I. (2011). Measurement of Intracellular Calcium Concentration in Pancreatic Acini. The Pancreapedia: Exocrine Pancreas Knowledge Base, DOI:10.3998/panc.2011.34

## 5. References

1. **Alzayady KJ, Wagner LE, 2nd, Chandrasekhar R, Monteagudo A, Godiska R, Tall GG, et al.** Functional inositol 1,4,5-trisphosphate receptors assembled from concatenated homo- and heteromeric subunits. *J Biol Chem* 288(41): 29772-29784,2013. [PMID: 23955339](#).
2. **Alzayady KJ, Wang L, Chandrasekhar R, Wagner LE, 2nd, Van Petegem F and Yule DI.** Defining the stoichiometry of inositol 1,4,5-trisphosphate binding required to initiate Ca<sup>2+</sup> release. *Sci Signal* 9(422): ra35,2016. [PMID: 27048566](#).
3. **Anyatonwu G and Joseph SK.** Surface accessibility and conformational changes in the N-terminal domain of type I inositol trisphosphate receptors: studies using cysteine substitution mutagenesis. *J Biol Chem* 284(12): 8093-8102,2009. [PMID: 19141613](#).
4. **Anyatonwu G, Khan MT, Schug ZT, da Fonseca PC, Morris EP and Joseph SK.** Calcium-dependent conformational changes in inositol trisphosphate receptors. *J Biol Chem* 285(32): 25085-25093,2010. [PMID: 20530483](#).
5. **Ashby MC, Camello-Almaraz C, Gerasimenko OV, Petersen OH and Tepikin AV.** Long distance communication between muscarinic receptors and Ca<sup>2+</sup> release channels revealed by carbachol uncaging in cell-attached patch pipette. *J Biol Chem* 278(23): 20860-20864,2003. [PMID: 12657637](#)
6. **Bayerdorffer E, Streb H, Eckhardt L, Haase W and Schulz I.** Characterization of calcium uptake into rough endoplasmic reticulum of rat pancreas. *J Membr Biol* 81(1): 69-82,1984. [PMID: 6208363](#).
7. **Betzenhauser MJ, Fike JL, Wagner LE, 2nd and Yule DI.** Protein kinase A increases type-2 inositol 1,4,5-trisphosphate receptor activity by phosphorylation of serine 937. *J Biol Chem* 284(37): 25116-25125,2009. [PMID: 19608738](#).
8. **Betzenhauser MJ, Wagner LE, 2nd, Iwai M, Michikawa T, Mikoshiba K and Yule DI.** ATP modulation of Ca<sup>2+</sup> release by type-2 and type-3 inositol (1, 4, 5)-triphosphate receptors. Differing ATP sensitivities and molecular determinants of action. *J Biol Chem* 283(31): 21579-21587,2008. [PMID: 18505727](#).
9. **Betzenhauser MJ, Wagner LE, 2nd, Park HS and Yule DI.** ATP regulation of type-1 inositol 1,4,5-trisphosphate receptor activity does not require walker A-type ATP-binding motifs. *J Biol Chem* 284(24): 16156-16163,2009. [PMID: 19386591](#).
10. **Betzenhauser MJ, Wagner LE, 2nd, Won JH and Yule DI.** Studying isoform-specific inositol 1,4,5-trisphosphate receptor function and regulation. *Methods* 46(3): 177-182,2008. [PMID: 18929664](#).
11. **Betzenhauser MJ and Yule DI.** Regulation of inositol 1,4,5-trisphosphate receptors by phosphorylation and adenine nucleotides. *Curr Top Membr* 66C: 273-298,2010. [PMID: 22353484](#).

12. **Bezprozvanny I.** The inositol 1,4,5-trisphosphate receptors. *Cell Calcium* 38(3-4): 261-272,2005. [PMID: 16102823](#).
13. **Bezprozvanny I, Bezprozvannaya S and Ehrlich BE.** Caffeine-induced inhibition of inositol(1,4,5)-trisphosphate-gated calcium channels from cerebellum. *Mol Biol Cell* 5(1): 97-103,1994. [PMID: 8186468](#).
14. **Bezprozvanny I, Watras J and Ehrlich BE.** Bell-shaped calcium-response curves of Ins(1,4,5)P<sub>3</sub>- and calcium-gated channels from endoplasmic reticulum of cerebellum. *Nature* 351(6329): 751-754,1991. [PMID: 1648178](#).
15. **Boehning D and Joseph SK.** Direct association of ligand-binding and pore domains in homo- and heterotetrameric inositol 1,4,5-trisphosphate receptors. *EMBO J* 19(20): 5450-5459,2000. [PMID: 11032812](#).
16. **Boehning D, Mak DO, Foskett JK and Joseph SK.** Molecular determinants of ion permeation and selectivity in inositol 1,4,5-trisphosphate receptor Ca<sup>2+</sup> channels. *J Biol Chem* 276(17): 13509-13512,2001. [PMID: 11278266](#).
17. **Chandrasekhar R, Alzayady KJ, Wagner LE, 2nd and Yule DI.** Unique Regulatory Properties of Heterotetrameric Inositol 1,4,5-Trisphosphate Receptors Revealed by Studying Concatenated Receptor Constructs. *J Biol Chem* 291(10): 4846-4860,2016. [PMID: 26755721](#).
18. **Chandrasekhar R, Alzayady KJ and Yule DI.** Using concatenated subunits to investigate the functional consequences of heterotetrameric inositol 1,4,5-trisphosphate receptors. *Biochem Soc Trans* 43(3): 364-370,2015. [PMID: 26009177](#).
19. **Fan G, Baker ML, Wang Z, Baker MR, Sinyagovskiy PA, Chiu W, et al.** Gating machinery of InsP<sub>3</sub>R channels revealed by electron cryomicroscopy. *Nature* 527(7578): 336-341,2015. [PMID: 26458101](#).
20. **Fogarty KE, Kidd JF, Tuft DA and Thorn P.** Mechanisms underlying InsP<sub>3</sub>-evoked global Ca<sup>2+</sup> signals in mouse pancreatic acinar cells. *J Physiol* 526(3): 515-526,2000. DOI 10.1111/j.1469-7793.2000.t01-1-00515.x
21. **Foskett JK, White C, Cheung KH and Mak DO.** Inositol trisphosphate receptor Ca<sup>2+</sup> release channels. *Physiol Rev* 87(2): 593-658,2007. [PMID: 17429043](#).
22. **Futatsugi A, Nakamura T, Yamada MK, Ebisui E, Nakamura K, Uchida K, et al.** IP<sub>3</sub> receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism. *Science* 309(5744): 2232-2234,2005. [PMID: 16195467](#).
23. **Gafni J, Munsch JA, Lam TH, Catlin MC, Costa LG, Molinski TF, et al.** Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. *Neuron* 19(3): 723-733,1997. [PMID: 9331361](#).
24. **Giovannucci DR, Bruce JI, Straub SV, Arreola J, Sneyd J, Shuttleworth TJ, et al.** Cytosolic Ca<sup>2+</sup> and Ca<sup>2+</sup>-activated Cl<sup>-</sup> current dynamics: insights from two functionally distinct mouse exocrine cells. *J Physiol* 540(Pt 2): 469-484,2002. [PMID: 11956337](#).
25. **Hamada K, Miyata T, Mayanagi K, Hirota J and Mikoshiba K.** Two-state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by calcium. *J Biol Chem* 277(24): 21115-21118,2002. [PMID: 11980893](#).
26. **Hamada K, Miyatake H, Terauchi A and Mikoshiba K.** IP<sub>3</sub>-mediated gating mechanism of the IP<sub>3</sub> receptor revealed by mutagenesis and X-ray crystallography. *Proc Natl Acad Sci U S A* 114(18): 4661-4666,2017. [PMID: 28416699](#).
27. **Hirata K, Puhl T, O'Neill AF, Dranoff JA and Nathanson MH.** The type II inositol 1,4,5-trisphosphate receptor can trigger Ca<sup>2+</sup> waves in rat hepatocytes. *Gastroenterology* 122(4): 1088-1100,2002. [PMID: 11910359](#).
28. **Hirota J, Furuichi T and Mikoshiba K.** Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. *J Biol Chem* 274(48): 34433-34437,1999. [PMID: 10567423](#).
29. **Iwai M, Michikawa T, Bosanac I, Ikura M and Mikoshiba K.** Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors. *J Biol Chem* 282(17): 12755-12764,2007. [PMID: 17327232](#).
30. **Joseph SK, Boehning D, Pierson S and Nicchitta CV.** Membrane insertion, glycosylation, and oligomerization of inositol trisphosphate receptors in a cell-free translation system. *J Biol Chem* 272(3): 1579-1588,1997. [PMID: 8999831](#).
31. **Kasai H and Augustine GJ.** Cytosolic Ca<sup>2+</sup> Gradients Triggering Unidirectional Fluid Secretion from Exocrine Pancreas. *Nature* 348(6303): 735-738,1990. [PMID: 1701852](#)
32. **Kopil CM, Vais H, Cheung KH, Siebert AP, Mak DO, Foskett JK, et al.** Calpain-cleaved type 1 inositol 1,4,5-trisphosphate receptor (InsP<sub>3</sub>R1) has InsP<sub>3</sub>-independent gating and disrupts intracellular Ca<sup>2+</sup> homeostasis. *J Biol Chem* 286(41): 35998-36010,2011. [PMID: 21859719](#).

33. **Kruglov EA, Gautam S, Guerra MT and Nathanson MH.** Type 2 inositol 1,4,5-trisphosphate receptor modulates bile salt export pump activity in rat hepatocytes. *Hepatology* 54(5): 1790-1799,2011. [PMID: 21748767](#).
34. **Lee MG, Xu X, Zeng W, Diaz J, Kuo TH, Wuytack F, et al.** Polarized expression of Ca<sup>2+</sup> pumps in pancreatic and salivary gland cells. Role in initiation and propagation of [Ca<sup>2+</sup>]<sub>i</sub> waves. *J Biol Chem* 272(25): 15771-15776,1997. [PMID: 9188473](#).
35. **Li X, Zima AV, Sheikh F, Blatter LA and Chen J.** Endothelin-1-induced arrhythmogenic Ca<sup>2+</sup> signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP<sub>3</sub>)-receptor type 2-deficient mice. *Circ Res* 96(12): 1274-1281,2005. [PMID: 15933266](#).
36. **Lur G, Sherwood MW, Ebisui E, Haynes L, Feske S, Sutton R, et al.** InsP(3)receptors and Orai channels in pancreatic acinar cells: co-localization and its consequences. *Biochem J* 436(2): 231-239,2011. [PMID: 21568942](#).
37. **Mak DO, McBride S and Foskett JK.** Inositol 1,4,5-trisphosphate [correction of tris-phosphate] activation of inositol trisphosphate [correction of tris-phosphate] receptor Ca<sup>2+</sup> channel by ligand tuning of Ca<sup>2+</sup> inhibition. *Proc Natl Acad Sci U S A* 95(26): 15821-15825,1998. [PMID: 9861054](#).
38. **Maruyama T, Kanaji T, Nakade S, Kanno T and Mikoshiba K.** 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P<sub>3</sub>-induced Ca<sup>2+</sup> release. *J Biochem* 122(3): 498-505,1997. [PMID: 9348075](#).
39. **Matsumoto M, Nakagawa T, Inoue T, Nagata E, Tanaka K, Takano H, et al.** Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. *Nature* 379(6561): 168-171,1996. [PMID: 8538767](#).
40. **Mignery GA, Sudhof TC, Takei K and Decamilli P.** Putative receptor for inositol 1,4,5-trisphosphate similar to ryanodine receptor. *Nature* 342(6246): 192-195,1989. [PMID: 2554146](#)
41. **Missiaen L, Callewaert G, De Smedt H and Parys JB.** 2-Aminoethoxydiphenyl borate affects the inositol 1,4,5-trisphosphate receptor, the intracellular Ca<sup>2+</sup> pump and the non-specific Ca<sup>2+</sup> leak from the non-mitochondrial Ca<sup>2+</sup> stores in permeabilized A7r5 cells. *Cell Calcium* 29(2): 111-116,2001. [PMID: 11162848](#).
42. **Nathanson MH, Padfield PJ, O'Sullivan AJ, Burgstahler AD and Jamieson JD.** Mechanism of Ca<sup>2+</sup> wave propagation in pancreatic acinar cells. *J Biol Chem* 267(25): 18118-18121,1992. [PMID: 1517244](#).
43. **Onoue H, Tanaka H, Tanaka K, Doira N and Ito Y.** Heterooligomer of type 1 and type 2 inositol 1, 4, 5-trisphosphate receptor expressed in rat liver membrane fraction exists as tetrameric complex. *Biochem Biophys Res Commun* 267(3): 928-933,2000. [PMID: 10673393](#).
44. **Pantazaka E and Taylor CW.** Targeting of inositol 1,4,5-trisphosphate receptor to the endoplasmic reticulum by its first transmembrane domain. *Biochemical Journal* 425: 61-69,2010. [PMID: 19845505](#)
45. **Park HS, Betzenhauser MJ, Won JH, Chen J and Yule DI.** The type 2 inositol (1,4,5)-trisphosphate (InsP<sub>3</sub>) receptor determines the sensitivity of InsP<sub>3</sub>-induced Ca<sup>2+</sup> release to ATP in pancreatic acinar cells. *J Biol Chem* 283(38): 26081-26088,2008. [PMID: 18658132](#).
46. **Parker AKT, Gergely FV and Taylor CW.** Targeting of inositol 1,4,5-trisphosphate receptors to the endoplasmic reticulum by multiple signals within their transmembrane domains. *J Biol Chem* 279(22): 23797-23805,2004. [PMID: 15033979](#)
47. **Patel S, Joseph SK and Thomas AP.** Molecular properties of inositol 1,4,5-trisphosphate receptors. *Cell Calcium* 25(3): 247-264,1999. [PMID: 10378086](#).
48. **Ramos-Franco J, Galvan D, Mignery GA and Fill M.** Location of the permeation pathway in the recombinant type 1 inositol 1,4,5-trisphosphate receptor. *J Gen Physiol* 114(2): 243-250,1999. [PMID: 10436000](#).
49. **Sienaert I, De Smedt H, Parys JB, Missiaen L, Vanlingen S, Sipma H, et al.** Characterization of a cytosolic and a luminal Ca<sup>2+</sup> binding site in the type I inositol 1,4,5-trisphosphate receptor. *J Biol Chem* 271(43): 27005-27012,1996. [PMID: 8900188](#).
50. **Sienaert I, Missiaen L, De Smedt H, Parys JB, Sipma H and Casteels R.** Molecular and functional evidence for multiple Ca<sup>2+</sup>-binding domains in the type 1 inositol 1,4,5-trisphosphate receptor. *J Biol Chem* 272(41): 25899-25906,1997. [PMID: 9325322](#).
51. **Sneyd J, Han JM, Wang L, Chen J, Yang X, Tanimura A, et al.** On the dynamical structure of calcium oscillations. *Proc Natl Acad Sci U S A* 114(7): 1456-1461,2017. [PMID: 28154146](#).
52. **Soulsby MD and Wojcikiewicz RJ.** The type III inositol 1,4,5-trisphosphate receptor is phosphorylated by cAMP-dependent protein kinase at three sites. *Biochem J* 392(Pt 3): 493-497,2005. [PMID: 16107208](#).
53. **Streb H, Bayerdorffer E, Haase W, Irvine RF and Schulz I.** Effect of inositol-1,4,5-trisphosphate on isolated subcellular fractions of rat pancreas. *J Membr Biol* 81(3): 241-253,1984. [PMID: 6334162](#).
54. **Streb H, Irvine RF, Berridge MJ and Schulz I.** Release of Ca<sup>2+</sup> from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. *Nature* 306(5938): 67-69,1983. [PMID: 6605482](#).

55. **Sugawara H, Kurosaki M, Takata M and Kurosaki T.** Genetic evidence for involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor. *EMBO J* 16(11): 3078-3088,1997. [PMID: 9214625](#).
56. **Supattapone S, Worley PF, Baraban JM and Snyder SH.** Solubilization, purification, and characterization of an inositol trisphosphate receptor. *J Biol Chem* 263(3): 1530-1534,1988. [PMID: 2826483](#).
57. **Taylor CW and Laude AJ.** IP3 receptors and their regulation by calmodulin and cytosolic Ca<sup>2+</sup>. *Cell Calcium* 32(5-6): 321-334,2002. [PMID: 12543092](#).
58. **Thorn P, Lawrie AM, Smith PM, Gallacher DV and Petersen OH.** Local and global cytosolic Ca<sup>2+</sup> oscillations in exocrine cells evoked by agonists and inositol trisphosphate. *Cell* 74(4): 661-668,1993. [PMID: 8395347](#).
59. **Wagner LE, 2nd, Betzenhauser MJ and Yule DI.** ATP binding to a unique site in the type-1 S2- inositol 1,4,5-trisphosphate receptor defines susceptibility to phosphorylation by protein kinase A. *J Biol Chem* 281(25): 17410-17419,2006. [PMID: 16621795](#).
60. **Wang L, Alzayady KJ and Yule DI.** Proteolytic fragmentation of inositol 1,4,5-trisphosphate receptors: a novel mechanism regulating channel activity? *J Physiol* 594(11): 2867-2876,2016. [PMID: 26486785](#).
61. **Wang L, Wagner LE, 2nd, Alzayady KJ and Yule DI.** Region-specific proteolysis differentially regulates type 1 inositol 1,4,5-trisphosphate receptor activity. *J Biol Chem* 292(28): 11714-11726,2017. [PMID: 28526746](#).
62. **Williams JA and Yule DI.** Stimulus-secretion coupling in pancreatic acinar cells. . *Physiology of the Gastrointestinal Tract*. LR Johnson. 2: 2197, 2012.
63. **Wojcikiewicz RJ.** Type I, II, and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types. *J Biol Chem* 270(19): 11678-11683,1995. [PMID: 7744807](#).
64. **Wojcikiewicz RJ and He Y.** Type I, II and III inositol 1,4,5-trisphosphate receptor co-immunoprecipitation as evidence for the existence of heterotetrameric receptor complexes. *Biochem Biophys Res Commun* 213(1): 334-341,1995. [PMID: 7639754](#).
65. **Won JH, Cottrell WJ, Foster TH and Yule DI.** Ca<sup>2+</sup> release dynamics in parotid and pancreatic exocrine acinar cells evoked by spatially limited flash photolysis. *Am J Physiol Gastrointest Liver Physiol* 293(6): G1166-1177,2007. [PMID: 17901163](#).
66. **Yamamoto H, Kanaide H and Nakamura M.** Heparin specifically inhibits the inositol 1,4,5-trisphosphate-induced Ca<sup>2+</sup> release from skinned rat aortic smooth muscle cells in primary culture. *Naunyn Schmiedebergs Arch Pharmacol* 341(4): 273-278,1990. [PMID: 2333098](#).
67. **Yoshikawa F, Morita M, Monkawa T, Michikawa T, Furuichi T and Mikoshiba K.** Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. *J Biol Chem* 271(30): 18277-18284,1996. [PMID: 8663526](#).
68. **Yule DI, Betzenhauser MJ and Joseph SK.** Linking structure to function: Recent lessons from inositol 1,4,5-trisphosphate receptor mutagenesis. *Cell Calcium* 47(6): 469-479,2010. [PMID: 20510450](#).
69. **Yule DI, Ernst SA, Ohnishi H and Wojcikiewicz RJ.** Evidence that zymogen granules are not a physiologically relevant calcium pool. Defining the distribution of inositol 1,4,5-trisphosphate receptors in pancreatic acinar cells. *J Biol Chem* 272(14): 9093-9098,1997. [PMID: 9083036](#).